Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 2 | 8 |
| 1997 | 7 | 1 | 8 |
| 1998 | 10 | 2 | 12 |
| 1999 | 7 | 0 | 7 |
| 2000 | 8 | 3 | 11 |
| 2001 | 4 | 3 | 7 |
| 2002 | 6 | 7 | 13 |
| 2003 | 8 | 7 | 15 |
| 2004 | 6 | 5 | 11 |
| 2005 | 13 | 5 | 18 |
| 2006 | 11 | 4 | 15 |
| 2007 | 10 | 4 | 14 |
| 2008 | 23 | 8 | 31 |
| 2009 | 21 | 9 | 30 |
| 2010 | 19 | 12 | 31 |
| 2011 | 20 | 15 | 35 |
| 2012 | 20 | 5 | 25 |
| 2013 | 21 | 6 | 27 |
| 2014 | 32 | 12 | 44 |
| 2015 | 27 | 13 | 40 |
| 2016 | 14 | 22 | 36 |
| 2017 | 28 | 18 | 46 |
| 2018 | 43 | 16 | 59 |
| 2019 | 42 | 16 | 58 |
| 2020 | 29 | 24 | 53 |
| 2021 | 17 | 40 | 57 |
| 2022 | 7 | 40 | 47 |
| 2023 | 6 | 42 | 48 |
| 2024 | 26 | 22 | 48 |
| 2025 | 34 | 7 | 41 |
| 2026 | 28 | 8 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatr Blood Cancer. 2026 Nov; 73(11):e70662.
-
Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study. Oncologist. 2026 Sep 09; 31(10).
-
Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy. Cancer Med. 2026 Sep; 15(9):e72281.
-
Diagnostic BMI and Induction Therapy Weight Change Associated With Hepatotoxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. Cancer Med. 2026 Sep; 15(9):e72218.
-
Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation. Cancer Lett. 2026 Oct 28; 659:218771.
-
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2?-?metastatic breast cancer: a single-institution experience. J Egypt Natl Canc Inst. 2026 Jul 28; 38(1).
-
Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials. Pediatr Blood Cancer. 2026 Sep; 73(9):e70522.
-
Prognostic Value of Tumor Response in Pediatric and Adult Patients With Ewing Sarcoma. Pediatr Blood Cancer. 2026 Sep; 73(9):e70420.
-
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast. 2026 Oct; 89:104881.
-
Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. Am J Hematol. 2026 Sep; 101 Suppl 3:42-49.